Newsletter Research Trend
Rats - The Animal Model that is Revitalizing Medical Research
Establishing appropriate animal models of disease is of vital importance in basic medical research – for which, rats and mice have become the animals of choice. Mice are considered the most important model animal for analyzing human gene functions due to its small size, low operational costs, relatively stable embryonic cells, and pliability for various genetic manipulations and gene editing. Read More ›
Research Trend COVID-19
Research Progress on SARS-CoV-2 Neutralizing Antibody and Vaccines
Though the current situation regarding COVID-19 is still severe, since July, many successes have been achieved on SARS-CoV-2 neutralizing antibody and Phase II clinical trials of SARS-CoV-2 vaccines. With the effort of scientists worldwide, results indicate that research will continue to make progress in the fight against COVID-19. Read More ›
Newsletter Research Trend COVID-19
ACE2 Catalog Models – Humanized, Conditional Knockin, and Knockout Mice
As the leading provider of custom animal model generation services, Cyagen’s R&D team began developing mouse models for studying the novel coronavirus in the early stages of the COVID-19 outbreak. Read More ›
Newsletter Research Trend Latest Discovery
RALY Gene Feature: New Implications in Metabolism and Cholesterogenesis
The heterogenous nuclear ribonucleoprotein (hnRNP) family are multifunctional complexes of RNA and protein present in the cell nucleus that serve critical roles in gene regulation. Multiple lines of evidence have linked hnRNP abnormalities as key pathobiological drivers of cancer and neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Read More ›
Newsletter
Rare Disease Grant Awards Announced for BeHEARD Challenge
Cyagen Biosciences recently announced our participation as a technology award sponsor for the 2019-2020 BeHEARD Rare Disease Science Challenge, hosted by the Rare Genomics Institute. Now that the competition has concluded, we are excited to release details regarding the winners of the technology awards and the rare disease studies they plan to pursue with their prizes. Read More ›
Newsletter
Cyagen’s Checklist for Your Return to the Lab
As scientists around the world continue to grapple with the implications of COVID-19 on their research, Cyagen remains available to assist with all your needs for in vivo model services and products. Our expert support team understands that researchers worldwide are up against many different barriers in starting their projects. Read More ›
Newsletter
New Cyagen Knockout Catalog Model Publication Alert – July 2020
From January through June of 2020, Cyagen received over 70 citations for our animal models, contributing to many advances across research fields. We have put together the below list of articles from high impact factor (IF) journals to provide insights into a variety of mouse model types, gene targets, research applications, and some of the most recent developments shown in scientific literature. Read More ›
COVID-19 Newsletter
COVID-19 Resource List for Researchers – ACE2 Animal Models and More
The pneumonia-like COVID-19 caused by the novel coronavirus (SARS-CoV-2) remains a huge medical challenge worldwide. To provide a wholistic guide for developing clinical treatments, vaccines, and antiviral drugs, it is of great significance to study the interaction mechanisms between severe acute respiratory syndrome (SARS) coronaviruses and host molecules, while also exploring the pathogenic process of coronaviruses. Read More ›
Research Trend Newsletter
Applications of Humanized Mouse Models in Drug Development Research
Humanized mice can be developed through a variety of genetic modification techniques, wherein human genes may directly replace endogenous mouse genes or be inserted into a safe locus, such as Rosa26. Read More ›
Research Trend Latest Discovery
Applications of Rat Models in Alzheimer's Disease Discovery Research
The predominant animal models currently used in the research of Alzheimer's disease (AD) are genetically modified mice. Although promising results have been achieved in this field, almost all corresponding clinical trials have failed, especially with regards to drug development centered on the amyloid hypothesis. Read More ›